Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)
WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.
FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.
BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.
Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.
We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.
Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.
Sheffield and London, UK - 25 May 2017. The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.
Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.
Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.
This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.
London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI
by Access AI
We met with The Economist to discuss how artificial intelligence (AI) and machine learning is helping to crack and transform the scientific method.